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Abstract
Objective
Patients with corticobasal syndrome (CBS) present with heterogeneous clinical features, in-
cluding asymmetric parkinsonism, dyspraxia, aphasia, and cognitive impairment; to better
understand the genetic etiology of this rare disease, we undertook a genetic analysis of
microtubule-associated protein tau (MAPT).
Methods
We performed a genetic evaluation ofMAPT mutations in 826 neurologically healthy controls
and 173 cases with CBS using the Illumina NeuroChip genotyping array.
Results
We identiﬁed 2 patients with CBS heterozygous for a rare mutation inMAPT (p.V363I) that is
located in the highly conserved microtubule-binding domain. One patient was pathologically
conﬁrmed and demonstrated extensive 4-repeat-tau-positive thread pathology, achromatic
neurons, and astrocytic plaques consistent with corticobasal degeneration (CBD).
Conclusions
We report 2 CBS cases carrying the rare p.V363I MAPT mutation, one of which was patho-
logically conﬁrmed as CBD. Our ﬁndings support the notion that this rare coding change is
pathogenic.
From the Neurodegenerative Disease Research Unit (S.A., M.S.S., S.W.S.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD;
Movement Disorders and Memory Unit (M.D.F., P.P.), Department of Neurology, University Hospital Mutua de Terrassa, and Fundacio´ per la Recerca Biome`dica i Social Mu´tua
Terrassa, Barcelona, Spain; Laboratory of Neurogenetics (J.D.), National Institutes on Aging, National Institutes of Health, Bethesda, MD; Neurology Service (L.I.), Hospital Universitari
Germans Trias, Pujol, Badalona, Spain; Department of Neurology (A.B., A.P., S.W.S.), Johns Hopkins University Medical Center, Baltimore, MD; Newcastle Institute for Ageing (C.M.M.),
Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Neurodegenerative Diseases (C.S., T.G.), Center of Neurology, Hertie-
Institute for Clinical Brain Research, University of Tuebingen, andGerman Center for Neurodegenerative Diseases, Germany; Department of Molecular and Clinical Neuroscience (E.J.,
H.R.M.), Institute of Neurology, University College London, United Kingdom; Department of Pathology (Neuropathology) (O.P., J.T.), Johns Hopkins University Medical Center,
Baltimore, MD; Department of Clinical Neurosciences (H.R.M.), Royal Free Campus UCL, Institute of Neurology, London, United Kingdom; Neurological Tissue Bank (E.G.), University of
Barcelona-Hospital Clinic, IDIBAPS, Barcelona, Spain; and Institute of Neurology (E.G.), Medical University of Vienna, Austria.
Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the NIH.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
Corticobasal syndrome (CBS) is a rare neurologic disease that
presents with heterogeneous motor symptoms and cognitive
impairment.1 A high misdiagnosis rate due to clinical het-
erogeneity limits eﬀorts to extend disease-modifying therapy
trials to this patient population. Improving the diagnostic
accuracy of complex neurodegenerative syndromes is an im-
portant, yet unmet need in the research community.
Although understanding of the genetic underpinnings of CBS
is limited, rare mutations in the microtubule-associated pro-
tein tau (MAPT) gene are implicated as a cause of CBS and
related tauopathy spectrum disorders.2–6 One of theseMAPT
mutations is the variant p.V363I (rs63750869; c.1087G>A:
NM_005910.5), located in the MAPT microtubule-binding
domain. Previously described in a small number of patients
with clinical tauopathy phenotypes (table 1), the mutation is
present at a very low frequency in population databases and is
hypothesized to be a disease-causing mutation with decreased
penetrance rather than a rare polymorphism.6–10 The rare
nature of the mutation makes it diﬃcult to demonstrate disease
segregation, and in silico prediction algorithms of this mutation
are inconclusive (table e-1, links.lww.com/NXG/A162).
We describe 2 CBS cases who were found to carry the rare
p.V363I MAPT mutation. In addition, we summarize the
clinicopathologic features of previously reported cases with
a coding mutation at the MAPT p.V363 residue. One of our
CBS cases had postmortem conﬁrmation, which found
abundant four-repeat tau accumulations consistent with cor-
ticobasal degeneration (CBD). As a pathologically conﬁrmed
case with this rare missense mutation, this case provides
supporting evidence for the pathogenic nature of the p.V363I
MAPT mutation.
Methods
Study population
Case 1 is a 73-year-old, right-handed, white woman who
presented to the NIH Clinical Center in Bethesda, MD, for
participation in genetic research. She was diagnosed with
probable CBS based on the consensus criteria.11 A commer-
cial genetic panel (Invitae, San Francisco, CA) that included
screening of the genes CHCHD10, DCTN, FUS, GRN,
TARDBP, VCP, UBQLN2, TBK1, PSEN1, PSEN2, APP, and
MAPT had previously identiﬁed that she was a carrier of the
MAPT p.V363I variant. Case 2 was identiﬁed by querying
a research database for the presence of the MAPT p.V363I
variant. This database contains genotype information on
European-ancestry individuals, including 826 neurologically
healthy controls and 961 patients with frontotemporal
dementia (FTD) spectrum disorders (n = 772 cases with
progressive supranuclear palsy [PSP], n = 173 patients with
CBS/CBD, n = 41 patients with FTD; sample characteristics
are summarized in table e-2 [links.lww.com/NXG/A162];
source of samples and number of samples per disease are de-
scribed in table e-3). Case 2 was clinically diagnosed with hemi-
parkinsonism, primary progressive aphasia, and probable CBS.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the respective institutional review
boards. Written informed consent for research participation
was obtained from all participants.
Genetic analysis and validation
For each participant, DNA was extracted from blood or brain
tissue using standard methods and followed by genotyping on
the NeuroChip platform (Illumina, San Diego, CA). This
aﬀordable genotyping array contains a tagging single nucle-
otide polymorphism backbone combined with high-yield
custom content that allows for rapid screening of ;180,000
mutations and risk variants previously implicated in neuro-
logic diseases, including the MAPT p.V363I variant. The
detailed contents of this versatile genotyping platform have
been described elsewhere.12 The MAPT p.V363I mutation
was only present in 2 patients (henceforth referred to as case 1
and case 2), and we validated the mutation via direct
Sanger sequencing using the following primers: forward
59-GTGGCCAGGTGGAAGTAAAA, reverse 59-ACATC-
CAGCCAGTCAACACA. To rule out other possible patho-
genic mutations in these 2 patients, we assessed the NeuroChip
data for damaging progranulin (PGRN) genemutations.We also
performed repeat-primed PCR screening of the C9orf72 repeat
using methods described elsewhere.13 APOE genotypes were
determined by extracting rs7412 and rs429358 as previously
described.12 MAPT haplotype status was determined by impu-
tation of the polymorphism rs1052553 (R2 = 0.99494), with the
“A” allele determining the H1 haplotype and the “G” allele
segregating with the H2 haplotype.14
Bioinformatic analysis
To better understand the eﬀects of the p.V363I variant,
a systematic literature review was conducted and summarized
in table 1. In silico predictive tools (SIFT, PolyPhen2,
FATHMM-XF, M-CAP, MutationTaster, CADD, ClinVar,
and ClinPred) were applied to classify the MAPT p.V363I
mutation.15–21 Sequence conservation analyses were per-
formed in T-Coﬀee.22 A previously described, cryo-electron
microscopy structure of the tau protoﬁbril was used for
3-dimensional protein modeling (ﬁgure 1).23 Allele frequency
diﬀerences between CBS cases and neurologically healthy
Glossary
CBD = corticobasal degeneration; CBS = corticobasal syndrome; FTD = frontotemporal dementia; MAPT = microtubule-
associated protein tau; PGRN = progranulin; PSP = progressive supranuclear palsy.
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Table 1 Clinicopathologic features of patients with a mutation at the highly conserved p.V363 residue of MAPT
No.
Clinical features Genetics
Pathology Country ReferenceClinical diagnosis Sex AAO AAD FH Neuroimaging finding(s) Mutation Haplotype
1 CBS F 70 NA + MRI: bilateral parietal atrophy p.V363I H1/H1 NA United
States
This report
2 CBS and PPA F Late
50s
62 − NA p.V363I H1/H1 CBD Spain This report
3 PPA (nonfluent variant) F 69 NA + SPECT: bilateral Sylvian hypoperfusion p.V363I H1/H1 NA Spain Munoz
et al.9
4 FTD (behavioral variant) F 53 61 + MRI: bilateral frontotemporal atrophy p.V363I H1/H1 NA Italy Anfossi
et al.8
5 PPA (semantic variant) F 46 NA − MRI: asymmetric temporopolar atrophy p.V363I NA NA Italy Bessi
et al.6
6 FTD and PPA (nonfluent
variant)
F 55 NA NA SPECT: bilateral Sylvian hypoperfusion p.V363I NA NA Italy Rossi
et al.7
7 PCA F 54 NA NA NA p.V363I NA NA Italy Rossi
et al.7
8 FTD, PPA (nonfluent
variant), and CBS
F 55 NA NA MRI: mild left frontal atrophy
SPECT: left frontotemporal predominant hypoperfusion
FDG-PET: left parietal hypometabolism
p.V363I H1/H1 NA Italy Rossi
et al.10
9 PCA F 51 N/A + MRI: slight, asymmetric atrophy of posterior temporoparietal and occipital
lobes; white matter abnormalities
FDG-PET: bilateral posterior temporo-occipital and right posterior
frontoparietal hypometabolism
p.V363I H1/H1 N/A Italy Rossi
et al.10
10 PSP M 53 NA + MRI: midbrain atrophy
DAT scan: bilateral dopaminergic denervation
p.V363A H1/H1 NA Italy Rossi
et al.10
Abbreviations: AAD = age at death; AAO = age at onset; CBS = corticobasal syndrome; CBD = corticobasal degeneration; DAT scan = dopamine transporter scan; FDG = fluorodeoxyglucose PET; FH = family history; +/− = present/
absent; FTD = frontotemporal dementia;MAPT =microtubule-associated protein tau; NA = not available or not applicable; PCA = posterior cortical atrophy; PPA = primary progressive aphasia; PSP = progressive supranuclear
palsy; SPECT = single-photon emission computed tomography.
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controls were determined using a Fisher exact test with
a signiﬁcance threshold of 0.05.
Neuropathology
The brain of case 2 was pathologically evaluated at the Neuro-
logical Tissue Bank of the IDIBPASBiobank in Barcelona, Spain,
after obtaining written informed consent from the patient’s rel-
atives for use of tissue for diagnostic and research purposes.
Hematoxylin and eosin staining was performed after standard
formalin ﬁxation and paraﬃn block sectioning of multiple cor-
tical and subcortical brain areas. Immunohistochemistry was
performed using phospho-tau (Ser202 andThr205)monoclonal
antibodies (AT8; 1:2000; Thermo Scientiﬁc, Rockford, IL) and
anti-4R-tau (RD4) antibodies. In addition, selected areas were
stained for ßA4-amyloid (6F/3D 1:400; Dako, Glostrup, Den-
mark), α-synuclein (KM51 2:200; Novocastra, Newcastle upon
Tyne, UK), and TDP43 protein (2E2-E3 1:500; Abnova, Taipei,
Taiwan) for identiﬁcation of concomitant pathologies.
Data availability
Deidentiﬁed data are available upon request from qualiﬁed
investigators.
Results
Genetic characteristics
In a cohort of 173 CBS cases, we identiﬁed 2 patients who
were heterozygous for the rare p.V363I (c.1087G>A: NM_
005910.5) mutation located in the highly conserved microtubule-
binding domain ofMAPT (Fisher exact test comparing CBS cases
with neurologically healthy controls p = 0.0299). Both patients
were homozygous for the H1 MAPT haplotype and carried no
pathogenic mutations in PGRN or C9orf72. The patients’ APOE
genotypes were e3/e3. TheMAPT p.V363I mutation was absent
in;1,800 additional samples, including 826 neurologically healthy
controls and 984 cases with diverse frontotemporal degeneration
spectrum disorders. Bioinformatic predictions demonstrated that
SIFT, PolyPhen2, MutationTaster, and ClinPred categorized the
variant as tolerated and benign, whereas ClinVar, FATHMM-XF,
M-CAP, and CADD predictions suggested a likely pathogenic
mutation (table e-1, links.lww.com/NXG/A162).
Clinicopathologic features
Case 1 is a 73-year-old, right-handed, white woman with
a medical history of hypertension, coronary artery disease, an
Figure 1 This schematic representation illustrates the location of the MAPT p.V363I mutation
A Cartesian genotype plot and electro-
pherograms of this mutation are
shown for both CBS cases compared
with a control (A). The mutation is lo-
calized within the highly conserved mi-
crotubule-binding domain (B). (C)
Position of the p.V363I mutation (arrow
heads) within the microtubule-binding
domain (highlighted in purple) relative
to the 3-dimensional reconstruction of
the tau protofibril.MAPT =microtubule-
associated protein tau.
4 Neurology: Genetics | Volume 5, Number 4 | August 2019 Neurology.org/NG
old segmental left parietal stroke at age 54 years that resolved
without residual neurologic deﬁcits, and major depressive
disorder. She was diagnosed with CBS at age 70 years after
developing progressive right-sided impairment of her dex-
terity, slowed gait, and imbalance resulting in backward falls. A
levodopa trial up to a maximum dose of 450 mg daily yielded
no beneﬁts. Over the course of 3 years, she gradually de-
veloped dysarthria, severe gait dysfunction rendering her
wheelchair-bound, asymmetric parkinsonism, hand dystonia,
apraxia, impaired word retrieval, and executive dysfunction.
Her neurologic examination demonstrated bradyphrenia with
a tendency to perseverate. She had severe ideomotor apraxia
that was more prominent in her dominant hand. She was
neglecting her right-sided space. Her speech was moderately
dysarthric. Cranial nerve examination showed slowed, hypo-
metric saccades (vertical more than horizontal), severe axial
and right-sided rigidity with only mild rigidity on the left,
bradykinesia, and dystonia with high-frequency/low-
amplitude tremor in her right hand. She had agraphesthesia
and astereognosis in her right hand. Reﬂexes were brisk
throughout. Primitive reﬂexes, including grasp and palmo-
mental reﬂexes, were present. She was unable to stand without
assistance and would spontaneously fall without support. MRI
of the brain demonstrated bilateral parietal atrophy with
proportional, ex vacuo dilatation of the lateral ventricles. Her
family history was notable for parkinsonism in her father (age
at onset;65 years). No DNAwas available from her father to
test for segregation. The patient is alive after a 3-year disease
duration.
Case 2 was a white woman who presented in her late 50s with
primary progressive aphasia, left-sided parkinsonism, and
CBS. The disease progressed to complete anarthria and severe
dysphagia. She died at age 62 years. Clinical data on this case
were limited. She had no known family history of dementia.
The patient’s neuropathologic ﬁndings were notable for
widespread, 4-repeat-tau-positive inclusions in cortical and
subcortical regions, including neurons and glial cells, consis-
tent with CBD (ﬁgure 2). Frequent achromatic neurons were
detected in frontal, parietal, and cingular cortices. These were
Figure 2 These images showcase the pertinent neuropathologic findings of case 2
Hematoxylin and eosin staining shows superficial spongiosis in the postcentral region (A), a large achromatic or ballooned cell (highlighted by asterisk in B),
andprominent nigral degenerationwith severe neuronal loss and abundant extracellular neuromelanin pigment (C). (D–I) Abnormal pTau (AT8) and 4-repeat-
tau-positive protein deposition on immunohistochemistry. Notable abnormal histopathologic findings included astrocytic plaques (D), frequent pretangles
with some focal cytoplasmic condensations (E), tangles, pretangles, and abundant threads in the substantia nigra (F), very abundant threads (arrow heads)
and coiled bodies (arrow) in the white matter (G and H), and abundant threads and pretangles in the striatum (I), overall consistent with the neuropathologic
findings observed in corticobasal degeneration. Magnification scale bars are indicated in the bottom right corner of each panel.
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associated with focal superﬁcial spongiosis, diﬀuse neuronal
loss, astrogliosis, and microglial activation in cortical areas,
including the motor cortex, and diﬀuse gliosis of the un-
derlying white matter. Prominent neuronal loss was noted in
the globus pallidus and in the substantia nigra. Immunohis-
tochemistry revealed astrocytic plaques, abundant pretangles,
ballooned neurons, and neuropil threads in the cortex,
abundant threads and pretangles in her basal ganglia, and
prominent white matter pathology with widespread threads
and coiled bodies involving also the brainstem. Remarkably,
there was also prominent involvement of the hippocampus,
including the granule cells of the dentate gyrus, without grain
pathology. Co-comitant pathologies included a moderate
amount of diﬀuse ßA4-amyloid deposits and few cored pla-
ques in cortical areas, as well as few neuronal and glial cyto-
plasmic TDP43 protein inclusions in the globus pallidus,
without frontal, temporal, or hippocampal involvement. No
α-synuclein aggregates were identiﬁed.
Discussion
We describe 2 CBS cases carrying the rare p.V363I MAPT
mutation located in the conserved microtubule-binding do-
main. One of the 2 cases was pathologically conﬁrmed,
demonstrating widespread, 4-repeat-tau-positive neuronal
and glial pathology consistent with CBD. This report
describes the pathology present in a p.V363IMAPTmutation
carrier providing further support for the notion that this
variant is likely disease causing. To date, this coding mutation
has been described in 7 neurodegenerative disease cases with
heterogeneous presentations, including FTD, primary pro-
gressive aphasia, and posterior cortical atrophy (table 1).6,8–10
Another mutation at the same residue (p.V363A) has been
described in a single case with clinically diagnosed PSP.10 Of
interest, all cases were female, had e3/e3 APOE genotypes,
and were homozygous for the MAPT H1 haplotype. The
average age at onset was 57 years, ranging from 46 to 70 years.
The 2 CBS cases presented here extend the disease onset.
This wide age spectrum is consistent with the pattern seen in
tauopathies associated with MAPT mutations and could in-
dicate a decreased, age-related penetrance.24
Among the cases, the initial disease manifestations were quite
varied, including gait disturbances, memory deﬁcits, and
personality changes. This heterogeneity is not unusual for
patients with MAPT mutations.25 The p.V363I mutation is
present in 3 of 62,784 people in the NHLBI TopMed Bravo
database (bravo.sph.umich.edu/freeze5/hg38/; allele fre-
quency: 0.0000239; date accessed: October 14, 2018) and in
2 of 60,702 individuals in ExAC (allele frequency: 0.0000167,
data accessed: October 14, 2018).26 The very rare presence
within population databases might be explained by in-
complete penetrance and late disease onset. In addition,
limited in vitro analyses in 1 case demonstrated that this
mutation leads to an increased propensity for microtubule
polymerization and the formation of tau protein oligomers.10
Because of the lack of familial genetic data, we were not able to
test for disease segregation, and this has not yet been reported
by other investigators.
We present a pathologically conﬁrmed patient with a p.V363I
MAPT mutation. The neuropathologic ﬁndings of this case
were consistent with CBD. An additional p.V363I carrier was
identiﬁed with a CBS phenotype. This mutation was absent in
neurologically healthy controls. Considering previous reports
on mutation carriers with information about sequence con-
servation, functional studies, and pathologic conﬁrmation, we
nominate the MAPT p.V363I change as a likely disease-
causing mutation. Identifying additional cases with this mu-
tation will be important to understand the natural history and
penetrance of this familial disease.
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